NCT00517894No Longer Available不适用
Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie0 个研究点开始时间: 2007年8月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.
详细描述
Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 and 70 years of age
- •Centrally reviewed, histologically proven diffuse large B-cell, anaplastic large-cell, or peripheral T-cell unspecified
- •Measurable disease
- •All stages
排除标准
- •Lymphoblastic or Burkitt histology
- •CNS-disease
- •HIV-positive
- •pregnant or lactating women
- •Pretreatment
- •Other malignancy
- •Concomitant diseases that forbid chemotherapy
研究者
相似试验
已完成
3 期
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's LymphomaLymphomaNCT00003595National Cancer Institute (NCI)120
已完成
不适用
Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer PatientsBreast NeoplasmsNeoplasm MetastasisNCT01232062Peking University Cancer Hospital & Institute46
已完成
2 期
High Dose CHOP in LymphomaNon-Hodgkin's LymphomaNCT00192764Rambam Health Care Campus45
撤回
3 期
R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCLDiffuse Large B-cell LymphomaNCT02054559Asan Medical Center
已完成
不适用
Dose-intensive weekly combination chemotherapy (cisplatin, vincristine, doxorubicin and etoposide) followed by cisplatin-etoposide therapy with concurrent thoracic irradiation: evaluation of a new treatment for limited-disease small-cell lung cancer.JPRN-C000000145West Japan Oncology Group20